ProQR Therapeutics (PRQR) Long-Term Deferred Tax (2022 - 2025)

ProQR Therapeutics' Long-Term Deferred Tax history spans 3 years, with the latest figure at $3.5 million for Q4 2024.

  • For Q4 2024, Long-Term Deferred Tax fell 18.73% year-over-year to $3.5 million; the TTM value through Dec 2024 reached $3.5 million, down 18.73%, while the annual FY2024 figure was $3.5 million, 18.13% down from the prior year.
  • Long-Term Deferred Tax for Q4 2024 was $3.5 million at ProQR Therapeutics, down from $4.3 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $4.3 million in Q4 2023 and bottomed at $3.5 million in Q4 2024.
  • The 3-year median for Long-Term Deferred Tax is $4.0 million (2022), against an average of $3.9 million.
  • The largest annual shift saw Long-Term Deferred Tax increased 7.13% in 2023 before it decreased 18.73% in 2024.
  • A 3-year view of Long-Term Deferred Tax shows it stood at $4.0 million in 2022, then increased by 7.13% to $4.3 million in 2023, then fell by 18.73% to $3.5 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Long-Term Deferred Tax are $3.5 million (Q4 2024), $4.3 million (Q4 2023), and $4.0 million (Q4 2022).